Найти
Результаты поиска
Найден один результат.
-
COMPARATIVE EFFICACY AND SAFETY OF BARICITINIB PLUS SULFASALAZINE VERSUS TNF-Α INHIBITORS AND SULFASALAZINE MONOTHERAPY IN REACTIVE ARTHRITIS: A 12-MONTH RANDOMIZED STUDY
Reactive arthritis (ReA) is a post-infectious spondyloarthritis characterized by arthritis, enthesitis, and extra-articular features. Conventional treatments such as sulfasalazine (SSZ) show modest benefit, while TNF-α inhibitors are effective but limited by cost and accessibility. Baricitinib, a JAK1/2 inhibitor, offers a novel oral therapeutic strategy, though evidence in ReA is scarce.
1 - 1 из 1 результатов